Literature DB >> 19487254

Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver.

Jin Kyung Lee1, Koji Abe, Arlene S Bridges, Nita J Patel, Thomas J Raub, Gary M Pollack, Kim L R Brouwer.   

Abstract

Breast cancer resistance protein (BCRP, ABCG2) is expressed in the hepatic canalicular membrane and mediates biliary excretion of xenobiotics including sulfate and glucuronide metabolites of some compounds. Hepatic Bcrp expression is sex-dependent, with higher expression in male mice. The hypothesis that sex-dependent Bcrp expression influences the hepatobiliary disposition of phase II metabolites was tested in the present study using acetaminophen (APAP) and the generated APAP glucuronide (AG) and sulfate (AS) metabolites in single-pass in situ perfused livers from male and female wild-type and Abcg(-/-) (Bcrp-deficient) mice. Pharmacokinetic modeling was used to estimate parameters governing the hepatobiliary disposition of APAP, AG, and AS. In wild-type mice, the biliary excretion rate constant was 2.5- and 7-fold higher in males than in females for AS and AG, respectively, reflecting male-predominant Bcrp expression. Sex-dependent differences in AG biliary excretion were not observed in Bcrp-deficient mice, and AS biliary excretion was negligible. Interestingly, sex-dependent basolateral excretion of AG (higher in males) and AS (higher in females) was noted in wild-type mice with a similar trend in Bcrp-deficient mouse livers, reflecting an increased rate constant for AG formation in male and AS formation in female mouse livers. In addition, the rate constant for AS basolateral excretion was increased significantly in female mouse livers compared with that in male mouse livers. It is interesting to note that multidrug resistance-associated protein 4 was higher in female than in male mouse livers. In conclusion, sex-dependent differences in conjugation and transporter expression result in profound differences in the hepatobiliary disposition of AG and AS in male and female mouse livers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487254      PMCID: PMC2729328          DOI: 10.1124/dmd.109.026815

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  27 in total

1.  Tissue distribution and ontogeny of sulfotransferase enzymes in mice.

Authors:  Yazen Alnouti; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2006-06-28       Impact factor: 4.849

2.  Altered hepatobiliary disposition of 5 (and 6)-carboxy-2',7'-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice.

Authors:  Ken-Ichi Nezasa; Xianbin Tian; Maciej J Zamek-Gliszczynski; Nita J Patel; Thomas J Raub; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2006-01-24       Impact factor: 3.922

3.  Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.

Authors:  Gracia Merino; Antonius E van Herwaarden; Els Wagenaar; Johan W Jonker; Alfred H Schinkel
Journal:  Mol Pharmacol       Date:  2005-02-18       Impact factor: 4.436

4.  Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms.

Authors:  M H Court; S X Duan; L L von Moltke; D J Greenblatt; C J Patten; J O Miners; P I Mackenzie
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

5.  Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene.

Authors:  José E Manautou; Dirk R de Waart; Cindy Kunne; Noam Zelcer; Michael Goedken; Piet Borst; Ronald Oude Elferink
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

6.  Hepatic intracellular distribution of foreign compounds in relation to their biliary excretion.

Authors:  W G Levine; R W Singer
Journal:  J Pharmacol Exp Ther       Date:  1972-11       Impact factor: 4.030

7.  Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1.

Authors:  Maciej J Zamek-Gliszczynski; Keith A Hoffmaster; Xianbin Tian; Rong Zhao; Joseph W Polli; Joan E Humphreys; Lindsey O Webster; Arlene S Bridges; J Cory Kalvass; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2005-04-28       Impact factor: 3.922

8.  ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport.

Authors:  Rinako Nakagawa; Yoshikazu Hara; Hiroharu Arakawa; Susumu Nishimura; Hideya Komatani
Journal:  Biochem Biophys Res Commun       Date:  2002-12-13       Impact factor: 3.575

9.  Hepatic disposition of acetaminophen and metabolites. Pharmacokinetic modeling, protein binding and subcellular distribution.

Authors:  S D Studenberg; K L Brouwer
Journal:  Biochem Pharmacol       Date:  1993-08-17       Impact factor: 5.858

10.  Akt signaling regulates side population cell phenotype via Bcrp1 translocation.

Authors:  Masaki Mogi; Jiang Yang; Jean-Francois Lambert; Gerald A Colvin; Ichiro Shiojima; Carsten Skurk; Ross Summer; Alan Fine; Peter J Quesenberry; Kenneth Walsh
Journal:  J Biol Chem       Date:  2003-07-08       Impact factor: 5.157

View more
  10 in total

1.  UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP.

Authors:  Wen Jiang; Beibei Xu; Baojian Wu; Rong Yu; Ming Hu
Journal:  Drug Metab Dispos       Date:  2011-11-09       Impact factor: 3.922

Review 2.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

3.  A novel defensive mechanism against acetaminophen toxicity in the mouse lateral nasal gland: role of CYP2A5-mediated regulation of testosterone homeostasis and salivary androgen-binding protein expression.

Authors:  Xin Zhou; Yuan Wei; Fang Xie; Christina M Laukaitis; Robert C Karn; Kerri Kluetzman; Jun Gu; Qing-Yu Zhang; Dean W Roberts; Xinxin Ding
Journal:  Mol Pharmacol       Date:  2011-01-20       Impact factor: 4.436

4.  A new strategy to rapidly evaluate kinetics of glucuronide efflux by breast cancer resistance protein (BCRP/ABCG2).

Authors:  Baojian Wu; Wen Jiang; Taijun Yin; Song Gao; Ming Hu
Journal:  Pharm Res       Date:  2012-07-03       Impact factor: 4.200

Review 5.  Role and Regulation of Hepatobiliary ATP-Binding Cassette Transporters during Chemical-Induced Liver Injury.

Authors:  Carolina I Ghanem; Jose E Manautou
Journal:  Drug Metab Dispos       Date:  2022-08-01       Impact factor: 3.579

6.  Lower susceptibility of female mice to acetaminophen hepatotoxicity: Role of mitochondrial glutathione, oxidant stress and c-jun N-terminal kinase.

Authors:  Kuo Du; C David Williams; Mitchell R McGill; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2014-09-16       Impact factor: 4.219

Review 7.  Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  Pharm Res       Date:  2013-03-06       Impact factor: 4.200

8.  Prenatal and perinatal analgesic exposure and autism: an ecological link.

Authors:  Ann Z Bauer; David Kriebel
Journal:  Environ Health       Date:  2013-05-09       Impact factor: 5.984

9.  Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates.

Authors:  Jan B Koenderink; Jeroen J M W van den Heuvel; Ab Bilos; Galvin Vredenburg; Nico P E Vermeulen; Frans G M Russel
Journal:  Arch Toxicol       Date:  2020-05-29       Impact factor: 5.153

10.  Sex Difference of Egfr Expression and Molecular Pathway in the Liver: Impact on Drug Design and Cancer Treatments?

Authors:  Lishi Wang; Jianqi Xiao; Weikuan Gu; Hong Chen
Journal:  J Cancer       Date:  2016-03-20       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.